Sequenom, Inc. (NASDAQ:SQNM; San Diego, CA) says its MassARRAY Compact 96 system targets lower throughput basic and clinical laboratories. The matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based nucleic acid analysis platform quantitatively measures genetic target material and its variations. It promises accuracy, sensitivity, and optimal cost per sample (as low as $.08 per genotype) in experiments involving fewer than 500 genetic targets.
According to Sequenom, MassARRAY Compact 96 system provides exceptional performance for the most demanding applications, including highly sensitive and specific detection of low frequency mutations that are typically undetectable using conventional techniques. The technology lets researchers generate assays against any biomarkers they wish, and quickly and easily make changes to assays and biomarkers throughout the validation process.
MassARRAY technology supports key genomic applications, including single nucleotide polymorphism (SNP) genotyping, quantitative gene expression, and copy number variation (CNV) analysis, providing a multi-faceted view of a researcher's biological system of interest.
For more information see the MassARRAY Compact 96 system page on Sequenom's website.
---
original press release
SEQUENOM Announces Launch of MassARRAY Compact 96 System
New System Delivers Fast, Efficient, Cost-Effective Solution for Clinical Research
SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (NASDAQ:SQNM) today announced the launch of the MassARRAY Compact 96 system.
This generation of the MassARRAY system now addresses the needs of lower throughput laboratories. The combination of features of the new MassARRAY Compact 96 system - accuracy, sensitivity, and now the ability to cost-effectively run fewer samples - make this an ideal system for use in basic and clinical laboratories.
With the addition of the MassARRAY Compact 96 system SEQUENOM now offers genetic analysis solutions to serve the needs of any sized laboratory.
The MassARRAY Compact 96 system delivers:
-- exceptional performance which makes it ideal for the most demanding
applications; and
-- highly sensitive and specific mass spec-based detection of low
frequency mutations that are typically undetected using conventional
techniques.
The technology allows researchers to generate assays against any biomarkers they desire to validate, and to quickly and easily make changes to assays and biomarkers throughout the validation process.
MassARRAY technology supports key genomic applications, including single nucleotide polymorphism (SNP) genotyping, quantitative gene expression, and copy number variation (CNV) analysis, providing a multi-faceted view of a researcher's biological system of interest.
"Replacing other platforms that are limited to looking at tens of samples per week, our range of MassARRAY system products now allows for the analysis of hundreds through thousands of samples per day," said Mike Monko, senior vice president of sales & marketing at SEQUENOM. "MassARRAY technology enables detection of the most common molecular biomarker classes - somatic mutations via the OncoCarta mutation panel, SNPs, CNVs, methylation patterns, expression signatures - with an unmatched combination of quantitative accuracy and sensitivity. This is the type of high data quality that can potentially push biomarkers to clinical utilization and make the promise of personalized medicine a reality."
About MassARRAY
SEQUENOM's proprietary MassARRAY system is a high performance matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based nucleic acid analysis platform that quantitatively measures genetic target material and its variations in a rapid, accurate, and cost efficient manner. SEQUENOM's MassARRAY system facilitates a number of nucleic acid analysis applications including SNP genotyping and allelotyping, CNV analysis, quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control.
About SEQUENOM
SEQUENOM is a life sciences company committed to providing the best genetic analysis products that translate the results of genomic science into solutions for molecular diagnostics, biomedical research, translational research and molecular medicine applications. As an industry innovator in DNA analysis technology, SEQUENOM's MassARRAY system allows a direct mass measurement of nucleic acids, providing unparalleled precision and quantification. On the diagnostics front, SEQUENOM is developing a comprehensive portfolio of prenatal test methods by combining the versatility of the MassARRAY system with the company's SEQureDx(TM) technology, which enables the detection of circulating cell-free fetal nucleic acids in a maternal blood sample. The company is also developing tests for oncology, infectious diseases and other disorders. The company was founded in 1994 and is headquartered in San Diego, California. For more information please visit http://www.sequenom.com/.
SEQUENOM , SEQureDx(TM), and MassARRAY are trademarks of SEQUENOM, Inc. All other trademarks and service marks are the property of their respective owners.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the performance of the MassARRAY Compact 96 system, the potential for clinical utilization of biomarkers, the promise of personalized medicine, and the Company's development of prenatal test methods and tests for oncology, infectious diseases and other disorders, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MassARRAY Compact 96 system, the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal and other diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, the independent investigation and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Source: SEQUENOM, Inc.
Web Site: http://www.sequenom.com/
Posted by Barbara G. Goode, [email protected], for BioOptics World.